Physician profile
Maxwell S Stem
NPI 1093033300
$8,096.74
in general payments reported to CMS, 2019-2025
13 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,915 · 2020: $17.56 · 2021: $44.86 · 2022: $115 · 2023: $225 · 2024: $350 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $7,029.69 | 2019-2025 | Vabysmo |
| Amgen INC. | $191.06 | 2025 | Tepezza |
| Abbvie INC. | $177.28 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $126.46 | 2021-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $124.80 | 2019 | |
| Alcon Vision LLC | $120.53 | 2024 | Clareon |
| Carl Zeiss Meditec USA, INC. | $102.67 | 2024 | Cirrus Hd-Oct |
| Bausch & Lomb Americas INC. | $87.64 | 2025 | Xipere |
| Alimera Sciences, INC. | $47.52 | 2023-2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $27.03 | 2023 | Syfovre |
| Astellas Pharma US INC | $24.76 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $21.19 | 2019 | |
| Sandoz INC. | $16.11 | 2025 | Cimerli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Stem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.